Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

 ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma

Compelling Response Rates to Date; Defined Regulatory Path to Registration

Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million

Management to Host Conference Call at 8:30 a.m. ET Today

https://finance.yahoo.com/news/chimerix-acquires-oncoceutics-expand-pipeline-110000574.html